These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29205665)

  • 1. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.
    Bayo J; Aviñó V; Toscano F; Jiménez F
    Breast J; 2018 Jul; 24(4):462-467. PubMed ID: 29205665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
    Van Belle H; Hurvitz SA; Gilbar PJ; Wildiers H
    Breast Cancer Res Treat; 2021 Dec; 190(3):357-372. PubMed ID: 34533681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
    Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
    J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
    van Ramshorst MS; van Werkhoven E; Mandjes IAM; Schot M; Wesseling J; Vrancken Peeters MTFD; Meerum Terwogt JM; Bos MEM; Oosterkamp HM; Rodenhuis S; Linn SC; Sonke GS
    Eur J Cancer; 2017 Mar; 74():47-54. PubMed ID: 28335887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.
    Lin B; Fan J; Liu F; Wen Y; Li J; Gao F; Zhang Y; Feng G; Du X; Chen W
    Technol Cancer Res Treat; 2023; 22():15330338231218152. PubMed ID: 38031361
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].
    Xin L; Zhang H; Zhang S; Cheng YJ; Liu Q; Xu L; Ye JM; Li T; Duan XN; Liu YH; Li ZH
    Zhonghua Wai Ke Za Zhi; 2021 Mar; 59(3):222-227. PubMed ID: 33685057
    [No Abstract]   [Full Text] [Related]  

  • 11. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
    Zardawi SJ; Nordman I; Zdenkowski N
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
    Sonke GS; Mandjes IA; Holtkamp MJ; Schot M; van Werkhoven E; Wesseling J; Vrancken Peeters MJ; Rodenhuis S; Linn SC
    Breast J; 2013; 19(4):419-26. PubMed ID: 23682812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
    Sugitani I; Ueda S; Sakurai T; Shigekawa T; Hirokawa E; Shimada H; Takeuchi H; Matsuura K; Misumi M; Fujiuchi N; Takahashi T; Hasebe T; Osaki A; Saeki T
    Int J Clin Oncol; 2017 Oct; 22(5):880-886. PubMed ID: 28547525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
    Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
    He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
    Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
    Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
    J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
    [No Abstract]   [Full Text] [Related]  

  • 18. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
    Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
    Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
    Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J
    Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.
    Rocque G; Onitilo A; Engel J; Pettke E; Boshoven A; Kim K; Rishi S; Waack B; Wisinski KB; Tevaarwerk A; Burkard ME
    Breast Cancer Res Treat; 2012 Jan; 131(2):713-21. PubMed ID: 22065290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.